Skip to Main Content

CHAPTER 1: INTRODUCTION TO COVID-19 AND CARDIOVASCULAR DISEASE

1. +
Zhou  P, Yang  X-L, Wang  X-G,  et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.  [PubMed: 32015507]
2. +
Nishiga  M, Wang  DW, Han  Y, Lewis  DB, Wu  JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17(9):543–558.  [PubMed: 32690910]
3. +
Lu  R, Zhao  X, Li  J,  et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl. 2020;395(10224):565–574.
4. +
Hoffmann  M, Kleine-Weber  H, Schroeder  S,  et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.  [PubMed: 32142651]
5. +
Sattar  Y, Ullah  W, Rauf  H,  et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. Int J Cardiol Heart Vasc. 2020;29:100589.  [PubMed: 32724831]

CHAPTER 2: COVID-19 AND ACUTE CORONARY SYNDROME (ACS)

1. +
Pinto  DS. Coronavirus disease 2019 (COVID-19): myocardial infarction and other coronary artery disease issues. UpToDate. 2020.
2. +
Cevik  M, Bamford  CGG, Ho  A. COVID-19 pandemic-a focused review for clinicians. Clin Microbiol Infect. 2020;26:842–847.  [PubMed: 32344166]
3. +
Liu  Y, Li  J, Feng  Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Crit Care. 2020;24(1):56.  [PubMed: 32070391]
4. +
Libby  P, Loscalzo  J, Ridker  PM,  et al. Inflammation, immunity, and infection in atherothrombosis: JACC Review Topic of the Week. J Am Coll Cardiol. 2018;72:2071.  [PubMed: 30336831]
5. +
Mafham  MM, Spata  E, Goldacre  R,  et al. COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England. Lancet. 2020;396(10248):381–389.  [PubMed: 32679111]
6. +
Wang  D, Hu  B, Hu  C,  et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA.[JAMA and JAMA Network Journals Full Text] 2020;323(11):1061–1069.  [PubMed: 32031570]

CHAPTER 3: COVID-19 AND THROMBOEMBOLISM

1. +
Wang  X, Sahu  KK, Cerny  J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2021;51(3):657–662.  [PubMed: 33063256]
2. +
Gasecka  A, Borovac  JA, Guerreiro  RA,  et al. Thrombotic complications in patients with COVID-19: pathophysiological mechanisms, diagnosis, and treatment. Cardiovasc Drugs Ther. 2021;35(2):215–229.  [PubMed: 33074525]
3. +
Hadid  T, Kafri  Z, Al-Katib  A. Coagulation and anticoagulation in COVID-19. Blood Rev. 2020;Oct 8:100761.
4. +
Salem  N, Atallah  B, El Nekidy  WS, Sadik  ZG, Park  WM, Mallat  J. Thromboelastography findings in critically ill COVID-19 patients. J Thromb Thrombolysis. 2020;51(4):961–965.  [PubMed: 33011896]
5. +
Avila  J, Long  B, Holladay  D, Gottlieb  M. Thrombotic complications of COVID-19. Am J Emerg ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.